JP2003515569A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003515569A5 JP2003515569A5 JP2001541535A JP2001541535A JP2003515569A5 JP 2003515569 A5 JP2003515569 A5 JP 2003515569A5 JP 2001541535 A JP2001541535 A JP 2001541535A JP 2001541535 A JP2001541535 A JP 2001541535A JP 2003515569 A5 JP2003515569 A5 JP 2003515569A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antigen
- positively charged
- charged residue
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010002352 Interleukin-1 Proteins 0.000 description 17
- 102000000589 Interleukin-1 Human genes 0.000 description 17
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 238000000034 method Methods 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 4
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16892899P | 1999-12-03 | 1999-12-03 | |
| US60/168,928 | 1999-12-03 | ||
| PCT/US2000/032813 WO2001039803A2 (en) | 1999-12-03 | 2000-12-04 | Interleukin-1 muteins useful as vaccine adjuvants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003515569A JP2003515569A (ja) | 2003-05-07 |
| JP2003515569A5 true JP2003515569A5 (enExample) | 2008-01-31 |
Family
ID=22613541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001541535A Pending JP2003515569A (ja) | 1999-12-03 | 2000-12-04 | ワクチンアジュバントとして有用なインターロイキン−１ムテイン |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6656462B2 (enExample) |
| EP (1) | EP1196193B1 (enExample) |
| JP (1) | JP2003515569A (enExample) |
| AT (1) | ATE413191T1 (enExample) |
| AU (1) | AU1813701A (enExample) |
| DE (1) | DE60040740D1 (enExample) |
| WO (1) | WO2001039803A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6270758B1 (en) * | 1998-10-08 | 2001-08-07 | Duke University | Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects |
| BRPI0616446A2 (pt) | 2005-09-28 | 2011-06-21 | Cytos Biotechnology Ag | composição contendo conjugados de interleucina-1, vacina, uso da vacina, composição farmacêutica, processo para a produção da composição ou da vacina, bem como medicamento |
| AU2007281934B2 (en) | 2006-01-18 | 2012-11-15 | University Of Chicago | Compositions and methods related to Staphylococcal bacterium proteins |
| CA2664418A1 (en) * | 2006-09-28 | 2008-04-03 | Cytos Biotechnology Ag | Interleukin-1 muteins linked to virus-like particles to treat il-1 associated diseases |
| US9138470B2 (en) * | 2007-11-02 | 2015-09-22 | The Johns Hopkins University | Multi-component L2 vaccine for prevention of human papilloma virus infection |
| US20110262477A1 (en) | 2008-10-06 | 2011-10-27 | University Of Chicago | Compositions and Methods Related to Bacterial EAP, EMP, and/or ADSA Proteins |
| HRP20160274T1 (hr) | 2009-04-03 | 2016-04-08 | University Of Chicago | Pripravci i metode vezane za varijante proteina a (spa) |
| US8389474B1 (en) * | 2009-07-14 | 2013-03-05 | Alan Anson Wanderer | Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion |
| WO2011100508A2 (en) | 2010-02-12 | 2011-08-18 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Methods and compositions related to glycoprotein-immunoglobulin fusions |
| EP2555794A4 (en) | 2010-04-05 | 2014-01-15 | Univ Chicago | COMPOSITIONS AND METHODS RELATING TO PROTEIN A (SPA) ANTIBODIES AS IMMUNE REACTION AMPLIFIERS |
| AU2011274367B2 (en) | 2010-07-02 | 2015-04-23 | The University Of Chicago | Compositions and methods related to protein A (SpA) variants |
| JP5793194B2 (ja) | 2010-09-09 | 2015-10-14 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 感染防御ブドウ球菌抗原が関与する方法および組成物 |
| US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
| WO2013162746A1 (en) | 2012-04-26 | 2013-10-31 | University Of Chicago | Staphylococcal coagulase antigens and methods of their use |
| WO2014085767A1 (en) * | 2012-11-29 | 2014-06-05 | University Of Rochester | Compositions and methods for treating immune conditions, including type1 diabetes |
| CN104740615A (zh) * | 2013-12-31 | 2015-07-01 | 上海索菲里奥生物医药科技发展有限公司 | IL-1β在制备用于治疗由金黄色葡萄球菌易感所引起的炎症的药物中的用途 |
| TWI601742B (zh) * | 2016-03-23 | 2017-10-11 | 國立清華大學 | 使宿主提早產生抗體及延長抗體保護時間的重組雞介白素１β蛋白質及其應用 |
| US10662226B2 (en) | 2016-10-28 | 2020-05-26 | The Regents of the University of Caiifomia | Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers |
| WO2019183500A1 (en) | 2018-03-23 | 2019-09-26 | Hung Chiung Yu | Coccidioides antigens and methods of their use |
| CA3139981A1 (en) | 2019-05-14 | 2020-11-19 | The University Of Chicago | Methods and compositions comprising staphylococcus protein a (spa) variants |
| CA3185087A1 (en) * | 2020-07-07 | 2022-01-13 | Nikolai Kley | Immunostimulatory adjuvants |
| US20250177514A1 (en) | 2022-01-28 | 2025-06-05 | Pfizer Inc. | Coronavirus antigen variants |
| WO2025027492A1 (en) | 2023-07-31 | 2025-02-06 | Pfizer Inc. | Coronavirus antigen variants |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5342614A (en) | 1984-12-21 | 1994-08-30 | Otsuka Pharmaceutical Co., Ltd. | Method of treating arthritus or inflammation with IL-1β or derivatives thereof |
| US5503841A (en) | 1985-09-20 | 1996-04-02 | Cetus Oncology Corporation | Human IL-2 as a vaccine adjuvant |
| JP2591615B2 (ja) * | 1986-03-14 | 1997-03-19 | 大塚製薬株式会社 | インターロイキン−１β誘導体及び医薬 |
| IT1217314B (it) | 1987-02-20 | 1990-03-22 | Sclavo Spa | Nonapeptide sintetico ad attivita'adiuvante capace di potenziare in vivo la risposta anticorporale |
| ATE165114T1 (de) * | 1989-02-27 | 1998-05-15 | New England Medical Center Inc | Il-1, dessen biologische aktivität inhibiert ist |
| DK0482076T3 (da) | 1989-07-14 | 1995-07-17 | American Cyanamid Co | Stabile vaccinepræparater indeholdende interleukiner |
| AU651949B2 (en) | 1989-07-14 | 1994-08-11 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
-
2000
- 2000-12-04 JP JP2001541535A patent/JP2003515569A/ja active Pending
- 2000-12-04 US US09/729,509 patent/US6656462B2/en not_active Expired - Fee Related
- 2000-12-04 AT AT00980942T patent/ATE413191T1/de not_active IP Right Cessation
- 2000-12-04 EP EP00980942A patent/EP1196193B1/en not_active Expired - Lifetime
- 2000-12-04 WO PCT/US2000/032813 patent/WO2001039803A2/en not_active Ceased
- 2000-12-04 DE DE60040740T patent/DE60040740D1/de not_active Expired - Fee Related
- 2000-12-04 AU AU18137/01A patent/AU1813701A/en not_active Abandoned
-
2003
- 2003-10-14 US US10/684,774 patent/US20040253208A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2001026681A3 (en) | Method of obtaining cellular immune responses from proteins | |
| JP2003526662A5 (enExample) | ||
| JP2003528155A5 (enExample) | ||
| EP1538209A3 (en) | Self-assembling recombinant hpv16 papillomavirus capsid proteins | |
| WO2003094849A3 (en) | Ferritin fusion proteins for use in vaccines and other applications | |
| JP2006510347A5 (enExample) | ||
| CA2078694A1 (en) | Hepatitis b vaccine | |
| JP2007534728A5 (enExample) | ||
| WO2002074783A3 (en) | Modified interferon beta with reduced immunogenicity | |
| CA2391843A1 (en) | Hcv vaccine compositions | |
| CA2674885A1 (en) | Anti-ige vaccines | |
| JP2003515569A (ja) | ワクチンアジュバントとして有用なインターロイキン−１ムテイン | |
| Trepo et al. | Pegylated interferon alfa-2B (PEG-intron) mono-therapy is superior to interferon alfa-2B (intron A) for the treatment of chronic hepatitis C | |
| PT1015595E (pt) | Peptidos derivados da proteina de ligacao (g) do virus sincicial respiratorio | |
| RU2319505C2 (ru) | Очищенные оболочечные белки вируса гепатита с для диагностического и терапевтического применения | |
| Heath | Cytokines as immunological adjuvants | |
| CA2337754A1 (en) | Recombinant multivalent malarial vaccine against plasmodium falciparum | |
| WO2002085941A3 (en) | Modified interferon alpha with reduced immunogenicity | |
| WO2024228149A3 (en) | Method for inducing an immune response | |
| EP1209226A3 (en) | Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70) | |
| JP2001516567A5 (enExample) | ||
| HUP0303310A2 (hu) | Csökkentett immunogenitású módosított ciliáris neurotrofikus faktor (CNTF) | |
| TW200509964A (en) | VP1 of foot-and-mouth disease virus | |
| AU6933296A (en) | Recombinant viral pseudo-particles and vaccinal and antitumoral applications thereof | |
| CA2128407A1 (en) | Synthetic peptides for a rubella vaccine |